louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05710445: Augmented Reality Heads-up Display to Improve Ultrasound Guided IV Access
Official title: Augmented Reality Heads-up Display to Improve Ultrasound Guided IV Access
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Phlebotomy
Keywords: Catheters
Augmented Reality
Ultrasound
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2023-02-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Subjects will be randomly assigned to one of two groups. In the first group intravenous catheters will be placed per standard of care. In the second group, the catheter will be placed while the physicians utilizes augmented reality.
Primary purpose: OTHER

Brief summary: The purpose of this study is to assess the utility of an augmented reality headset for visualization of ultrasound images during ultrasound guided placement of an intravenous catheter.

Detailed description: After being informed about the study, patients who require image guided intravenous access and give consent will have their intravenous catheter placed by a physician wearing mixed reality smart glasses. The mixed reality smart glasses will have an application that allows the physician to view the ultrasound images in a virtual monitor. The physician will then use the images viewed on this virtual monitor to guide placement of the intravenous catheter.

Eligibility criteria: Inclusion Criteria:

* Age ≥18 years
* Referral for US assisted placement

Exclusion Criteria:

- Urgent/emergent requirement for IV

Primary outcomes:
measure: Cannulation rate
timeFrame: At end of procedure, on average 30 minutes
Secondary outcomes:
measure: Cannulation attempts
timeFrame: At end of procedure, on average 30 minutes
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania
state: Pennsylvania
Study officials:
affiliation: University of Pennsylvania
name: Ali H Dhanaliwala, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06499545: Plantar Pressures After Pressure Release of the Flexor Digitorum Brevis Muscle Versus a Non-emission Laser.
Official title: Plantar Pressures After Pressure Release of the Flexor Digitorum Brevis Muscle Versus a Non-emission Laser: Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Manual Therapy
Myofascial Pain Syndrome
Foot
Flat Foot
Lead sponsor: Mayuben Private Clinic
Sponsor class: OTHER
First posted: 2024-07-12
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: In this study we will test the effects of pressure release on the Flexor digitorum brevis muscle on the plantar pressures variables using a pressure platform.


Eligibility criteria: Inclusion criteria:

* Participants who came to the clinic presenting with pain in both heels and who were diagnosed with active or latent myofascial trigger point in bilateral flexor digitorum brevis muscles.
* Myofascila trigger points of flexor digitorum brevis were the only ones diagnosed in the foot.
* All participants with normal body mass, without obesity.

Exclusion criteria:

* Diagnosis of lower limb injury, such as plantar fasciitis, tendinopathy, bursitis, ligamentous injuries.
* History of previous lower limb surgery.
* Participants will not be subjected to ankle stretching or any other treatment.
* Diabetes due to possible elevation of plantar pressure.
* Toe deformities such as hammertoes and hallux valgus due to possible alteration of plantar pressure.

Primary outcomes:
measure: Variables of plantar pressures with platform before non-emission laser
timeFrame: Through study completion, an average of 2 days
measure: Variables of plantar pressures with platform before pressure release
timeFrame: Through study completion, an average of 2 days
measure: Variable footprint planting surface with platform before non-emission laser
timeFrame: Through study completion, an average of 2 days
measure: Variable footprint plantar surface with platform before pressure release
timeFrame: Through study completion, an average of 2 days
measure: Variables of plantar pressures with platform after non-emission laser
timeFrame: Through study completion, an average of 2 days
measure: Variables of plantar pressures with platform after preassure release
timeFrame: Through study completion, an average of 2 days
measure: Variable footprint planting surface with platform after non-emission laser
timeFrame: Through study completion, an average of 2 days
measure: Variable footprint planting surface with platform after pressure release
timeFrame: Through study completion, an average of 2 days
Secondary outcomes:
Other outcomes:
Locations:
city: San Sebastián De Los Reyes
country: Spain
facility: Mayuben Clinic
state: Madrid
Study officials:
affiliation: Universidad Complutense de Madrid
name: Eva María Martínez-Jiménez, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00960245: Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
Official title: A Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: High Blood Pressure
Migraine Headaches
Chest Pain
Lead sponsor: Sandoz
Sponsor class: INDUSTRY
First posted: 2009-08-17
Enrollment: 34
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.


Eligibility criteria: Inclusion Criteria:

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.

Primary outcomes:
measure: Bioequivalence based on AUC and Cmax
timeFrame: 21 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: MeritCare Broadway Health Center
name: Terry L. Wolff, D.O.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06299345: The Effect of Motor Imagery Dosage on Motor Learning in Healthy Adults
Official title: The Effect of Motor Imagery Dosage on Motor Learning in Healthy Adults, A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Motor Imagery
Dosage
Motor Learning
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
Collaborators: name: Concordia University Wisconsin
First posted: 2024-03-07
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The goal of this clinical trial is to compare the effects of different durations of Motor Imagery (MI) practice and physical practice on motor performance enhancement in healthy adults. The main questions it aims to answer are:

* Does Motor Imagery (MI) practice improve motor performance?
* How do different doses of MI practice (low vs. high) compare to no MI practice in enhancing motor performance?

Participants:

* Be randomly assigned to one of three groups: no MI practice (control group), low dose MI practice (6 minutes per session), or high dose MI practice (12 minutes per session).
* Complete nine sessions over three weeks, practicing a timed mirror tracing task.
* Have their performance measured in each session by the time taken to complete the task and the number of errors made.

Compared the control group, low dose MI group, and high dose MI group to see if there are significant differences in motor performance enhancement, aiming to determine the effectiveness of MI and the optimal dose for practice.


Eligibility criteria: Inclusion Criteria:

* no history of motor dysfunction, coordination disorders, or surgical procedures in the past 6 months
* scored 4 or less on the Movement Imagery Questionnaire (MIQ) on the non-dominant hand.

Exclusion Criteria:

* Played the target task in the past 6 months
* Subjects were ambidextrous

Primary outcomes:
measure: Time
timeFrame: Time was measured at the end of each session, with intervals of 3 session/week for 3 weeks with total of 9 sessions. So, the research ended up with 9 reading for the time.
measure: Errors
timeFrame: Errors were counted at the end of each session, with intervals of 3 session/week for 3 weeks with total of 9 sessions. So, the research ended up with 9 reading for the time.
Secondary outcomes:
Other outcomes:
Locations:
city: Mequon
country: United States
facility: Concordia University Wisconsin
state: Wisconsin
city: Kafr Ash Shaykh
country: Egypt
facility: Kafrelshaikh University
Study officials:
affiliation: Associate Professor of Physical Therapy, Kafrelsheikh University
name: Ahmed M Kadry, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04069845: A Registry Study in Lymphoma Patients Treated With Liposomal Doxorubicin
Official title: A Registry Study on the Risk Factors of Interstitial Pneumonia in Lymphoma Patients Treated With Liposomal Doxorubicin
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lymphoma
Lead sponsor: Ruijin Hospital
Sponsor class: OTHER
First posted: 2019-08-28
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: de novo lymphoma patients

Brief summary: This study is to evaluate the incidence of interstitial pneumonia in lymphoma patients treated with liposomal doxorubucin. The treatment response and other adverse events will also be studied.


Eligibility criteria: Inclusion Criteria:

* histologically confirmed lymphoma
* 18-80 years
* ECOG\<= 2
* newly diagnosed lymphoma
* liposomal doxorubicin is planned in the treatment
* normal lung function
* no history or malignancy
* informed consented

Exclusion Criteria:

* history of malignancy, now in the treatment
* pregnant
* serious infection
* other uncontrollable conditions judged by the investigator

Primary outcomes:
measure: the incidence of interstitial pneumonia
timeFrame: up to one month after completion of study treatment
Secondary outcomes:
measure: overall response rate
timeFrame: 21 days after completion of study treatment
measure: adverse events
timeFrame: up to 30 days after completion of study treatment
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Ruijin Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT04129645: Safety and Efficacy of URS Stents in the Treatment of Ureteral Stricture
Official title: Prospective Observational Study for Assessment of the Efficacy and Safety of Allium Ureteral Stent Long-term Indwelling in the Treatment of Ureteral Stricture
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ureteral Stricture
Keywords: Ureteral
ureteral stent
ureteral stricture
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2019-10-17
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients suffering from ureteral obstruction that require treatment.

Brief summary: A prospective observational study aimed to assess the efficacy and safety of Allium ureteral stent long-term indwelling in the treatment of ureteral stricture.


Eligibility criteria: Inclusion Criteria:

1. Benign diseases: UPJ, ischemic injury caused by surgical separation, endoscopic surgery injury, heat injury by laser lithotripsy, infection (chronic inflammation, tuberculosis), peri-ureteral fibrosis caused by endometriosis, ureteral anastomotic stenosis after renal transplantation, ureteral fistula, multiple polyps;
2. Malignant diseases: ureteral anastomotic stricture after urinary diversion, stricture caused by compression of abdominal and/or pelvic tumors, stricture caused by urinary tract tumors, stricture caused by radiotherapy for colon or cervical cancer, ureteral fistula

Exclusion Criteria:

1. Combine with hypertonic neurogenic bladder (except for patients with long-term indwelling catheter)
2. Colon resection surgery patients -

Primary outcomes:
measure: Patency rate
timeFrame: Up to 36 months
measure: Indwelling time
timeFrame: Up to 36 months
measure: Device related serious adverse events
timeFrame: Up to 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peiking university people's hospital
state: Beijing
Study officials:
References:
Clinical trial NCT02899845: Study of Improving Gait Parameters When Using a Cane in "Light Touch" Condition in Elderly People With and Without Walking Difficulties
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Disorders of Balance
Lead sponsor: Assistance Publique Hopitaux De Marseille
Sponsor class: OTHER
First posted: 2016-09-14
Enrollment: 24
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This project aims to study the effect of haptic sensory information delivered at the hand using a cane in "light touch" or "light support" condition on postural stability and spatial and temporal gait parameters of elderly subjects with and without walking difficulties


Eligibility criteria: Inclusion Criteria:

* presence of gait disturbance or balance disorders defined by a geriatric assessment and / or a walking speed test

Exclusion Criteria:

* presence of acute problems or central or peripheral neurological severe sequelae
* occurrence of a recent fracture of the lower limbs or spinal fracture
* cognitive disorders
* presence of comorbidities: blindness, heart or severe respiratory failure, disabling osteoarthritis of the hands or legs, severe malnutrition, muscle atrophy, untreated orthostatic hypotension
* patients using a cane to a mechanical support

Primary outcomes:
measure: number of use of the cane
timeFrame: 12 mois
Secondary outcomes:
Other outcomes:
Locations:
city: Marseille
country: France
facility: Assistance Publique Hôpitaux de Marseille
Study officials:
affiliation: Assistance Publique Hôpitaux de Marseille
name: Urielle Desalbres
role: STUDY_DIRECTOR
References:
Clinical trial NCT04582045: Effect of Prophylactic Negative Pressure Versus Silver Impregnated Silicone Bandage on C-Section Infection Rates
Official title: Effect of Prophylactic Negative Pressure Versus Silver Impregnated Silicone Bandage on Cesarean Section Surgical Site Infection Rate
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: D001458
D011247
Keywords: infection
bandage
cesarean section
Lead sponsor: HealthPartners Institute
Sponsor class: OTHER
First posted: 2020-10-09
Enrollment: 1064
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adult women requiring cesarean section

Brief summary: Effect of Prophylactic Negative Pressure versus Silver Impregnated Silicone Bandage on Cesarean Section Surgical Site Infection Rate

Detailed description: Comparison of effect of Prophylactic Negative Pressure versus Silver Impregnated Silicone Bandage on Cesarean Section Surgical Site Infection Rate as compared to wound vacuum in high risk women and traditional border dressing in low risk women in adult women having uncomplicated cesarean section.

Eligibility criteria: Inclusion Criteria:

* adult women, pregnant

Exclusion Criteria:

* \<18 years old
* surgery complicated by non-routine surgeries (Such as appendectomy)

Primary outcomes:
measure: Infection Rate
timeFrame: 30 days from surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Paul
country: United States
facility: Regions Hospital
state: Minnesota
Study officials:
affiliation: Regions Hospital
name: Larry Goldenberg
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05742945: Can ILR Reduce the Risk of Arm Lymphedema?
Official title: Can Immediate Lymphatic Reconstruction With Lymphatico-Venous Anastomosis Reduce the Occurrence of Arm Lymphedema in Breast Cancer Patients After Axillary Lymph Node Dissection? A Prospective Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Breast Cancer Lymphedema
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2023-02-24
Enrollment: 240
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Breast cancer-related lymphedema (BCRL) is a debilitating, usually lifelong burden for breast cancer survivors. For the breast cancer patients receiving axillary lymph node dissection (ALND), the likelihood of BCRL is about 20%. Lymphatico-venous anastomosis (LVA) has been accepted as a method of treating extremity lymphedema. A few studies have mentioned the prophylactic effect of LVA on BCRL. However, there is still lack of a large-scale randomized controlled trial to corroborate its efficacy. Therefore, the goal of this study is to conduct a prospective randomized controlled trial to evaluate if immediate lymphatic reconstruction (ILR) with LVA could have a clinically significant effect on the reduction of BCRL occurrence.


Eligibility criteria: Inclusion Criteria:

1. Female patients with unilateral breast cancer
2. Going to receive axillary lymph node dissection, or sentinel lymph node biopsy but being highly suspected of axillary metastasis preoperatively

Exclusion Criteria:

1. Had received axillary lymph node dissection
2. Going to receive bilateral axillary lymph node dissections
3. Already have arm lymphedema
4. Allergy to the dye used intraoperatively

Primary outcomes:
measure: Arm lymphedema
timeFrame: Two years
Secondary outcomes:
measure: Drainage amount
timeFrame: Two weeks
measure: Seroma or lymphocele
timeFrame: One month
measure: PROM
timeFrame: Two years
measure: Subclinical lymphedema
timeFrame: Two years
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Hao-Chih Dai, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06951945: Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With Obesity
Official title: Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With Obesity: A Randomized, Bouble-Blind, Placebo-Controlled Phase Ib Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Obesity
Lead sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd
Sponsor class: INDUSTRY
First posted: 2025-04-30
Enrollment: 36
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with obesity. This study includes three multiple-ascending dose cohorts.


Eligibility criteria: Inclusion Criteria:

* Age between 18 and 65 years (inclusive), male or female;
* Body mass index (BMI) ≥ 28 kg/m²;
* Diet and exercise control for at least 3 months before screening visit, and less than 5% self-reported change within the last 3 months.

Exclusion Criteria:

* Type 1 diabetes, type 2 diabetes, gestational diabetes, or other types of diabetes;
* History of obesity attributable to endocrine diseases, monogenic mutations, or drug-induced causes, such as hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, acromegaly, or hypogonadism; or weight gain resulting from increased non-fat mass (e.g., edema);
* Presence of uncontrolled hypertension at screening: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg;
* Prolonged QTcF interval on 12-lead ECG at screening (QTcF≥450 ms for males, \>470 ms for females), PR interval \>200 ms, or the presence of long QT syndrome, second- or third-degree atrioventricular block, left or right bundle branch block, Wolff-Parkinson-White syndrome, or any other clinically significant arrhythmias (except sinus arrhythmia).

Primary outcomes:
measure: Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)
timeFrame: 78 days
Secondary outcomes:
measure: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of THDBH120.
timeFrame: Day 1 Pre-dose through Day 43
measure: Pharmacokinetics (PK): Maximum Drug Concentration (Cmax) of THDBH120
timeFrame: Day 1 Pre-dose through Day 43
measure: Change From Baseline in Body Weight
timeFrame: 43 days
measure: Number of Participants With Anti-THBHD120 Antibodies
timeFrame: 78 days
Other outcomes:
Locations:
city: Anhui
country: China
facility: The First Affiliated Hospital of Bengbu Medical University
city: Zhejiang
country: China
facility: Hangzhou First People's Hospital
Study officials:
References: